LARODOPA
LOE ApproachingNDAORALTABLETPriority Review
Approved
Jun 1970
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 43m ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LARODOPA is an oral tablet small-molecule NDA approved in 1970 for neurological indications. The exact mechanism of action and therapeutic indication are not specified in available data, but the product name suggests levodopa-based therapy. This legacy product represents a foundational treatment in its therapeutic category.
LOE Approaching
Loss-of-exclusivity approaching signals potential team restructuring; commercial focus shifting to generic transition management and stakeholder retention.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
LARODOPA offers limited near-term career growth given LOE-approaching status and zero linked job openings. Positions on this brand focus on defensive management, generic transition planning, and stakeholder retention rather than expansion or innovation.
Brand ManagerField Sales Representative
Worked on LARODOPA at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.